Occlutech

Executive Summary

Occlutech, founded in 2003 and headquartered in Schaffhausen, Switzerland, has established itself as a leading global supplier in structural heart disease solutions. The company focuses on congenital heart defects, stroke prevention, and heart failure, offering a portfolio of innovative occluders and implantable devices. Leveraging proprietary technology, Occlutech aims to improve patient outcomes through minimally invasive procedures, reducing the need for open-heart surgery. With a strong European base and expanding international footprint, the company addresses a large and growing market driven by aging populations and increasing prevalence of cardiovascular diseases. Occlutech differentiates itself through differentiated product design, clinical evidence, and robust intellectual property. The company is well-positioned to capture share in the multibillion-dollar structural heart market, driven by upcoming product launches and potential regulatory approvals in key regions. While private, its consistent innovation and established commercial presence suggest strong growth prospects. Near-term catalysts include regulatory milestones and clinical data readouts that could significantly enhance its competitive position and valuation.

Upcoming Catalysts (preview)

• Q3 2026CE Mark approval for next-generation left atrial appendage occluder75% success
• Q2 2026Positive 1-year follow-up data from pivotal trial for atrial septal defect device80% success
• H2 2026Strategic partnership or distribution agreement in Asia-Pacific region60% success